STOCK TITAN

[Form 4] APPLIED DNA SCIENCES INC Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Applied DNA Sciences reported an insider equity change on a Form 4. A director acquired 18,691 shares of common stock on 10/17/2025 with a reported price of $0 (transaction code A). Following the transaction, the reporting person beneficially owns 18,694 shares, held directly.

The filing notes that 100% of the restricted stock units vest upon 90 days from the date of grant, indicating the award structure tied to service over a short vesting period.

Applied DNA Sciences ha riportato un cambiamento di capitale da insider su un modulo 4. Un amministratore ha acquisito 18.691 azioni ordinarie il 17/10/2025 con un prezzo riportato di $0 (codice di transazione A). A seguito della transazione, la persona che riporta possiede beneficamente 18.694 azioni, detenute direttamente.

La dichiarazione indica che il 100% delle Restricted Stock Units matura entro 90 giorni dalla data di attribuzione, indicando la struttura dell'assegnazione legata al servizio durante un breve periodo di vesting.

Applied DNA Sciences reportó un cambio de capital de insiders en un Form 4. Un director/a adquirió 18,691 acciones comunes el 17/10/2025 con un precio informado de $0 (código de transacción A). Tras la operación, la persona que reporta posee beneficiosamente 18,694 acciones, mantenidas directamente.

La presentación señala que el 100% de las unidades de acciones restringidas vencen tras 90 días desde la fecha de la concesión, indicando la estructura del premio ligada al servicio durante un corto periodo de vesting.

Applied DNA Sciences는 Form 4에 내부자 지분 변경을 보고했습니다. 이사는 일반 주식 18,691주2025-10-17에 매입했고 보고된 가격은 $0 (거래 코드 A)입니다. 거래 후 보고자는 직접 보유18,694주의 주식을 지분 보유합니다.

파일링에는 제한 주식 선발의 100%그 주식 부여일로부터 90일 이내에 비로소 취득된다고 적혀 있어, 짧은 vesting 기간 동안의 서비스에 연계된 보상 구조를 나타냅니다.

Applied DNA Sciences a rapporté un changement d'intérêts d'initié sur un formulaire 4. Un administrateur a acquis 18 691 actions ordinaires le 17/10/2025 avec un prix indiqué de $0 (code de transaction A). Suite à la transaction, la personne déclarant détient bénévolement 18 694 actions, détenues directement.

Le dossier indique que 100% des unités d'actions restreintes se vénent 90 jours après la date d'attribution, indiquant la structure de la récompense liée au service sur une courte période de vesting.

Applied DNA Sciences meldete eine Insider-Aktienänderung auf einem Formular 4. Ein Direktor erwarb 18.691 Stammaktien am 17.10.2025 zu einem berichteten Preis von $0 (Transaktionscode A). Nach der Transaktion besitzt die meldende Person vorteilhaft 18.694 Aktien, direkt gehalten.

Die Einreichung vermerkt, dass 100% der Restricted Stock Units fällig werden 90 Tage nach dem Ausübungsdatum, was die Preisstruktur zeigt, die an eine Dienstzeit über einen kurzen Vesting-Zeitraum gebunden ist.

Applied DNA Sciences أبلغت عن تغيير في أسهم insider على نموذج 4. اشترى مدير 18,691 سهماً من الأسهم العادية في 17/10/2025 بسعر مبلّغ عنه $0 (رمز المعاملة A). عقب الصفقة، يمتلك الشخص المبلغ عنه بشكل مستفيد 18,694 سهماً بشكل مباشر.

تذكر الوثيقة أن 100% من وحدات الأسهم المقيدة تتفتح بعد 90 يوماً من تاريخ المنح، مما يشير إلى هيكل الجائزة المرتبط بالخدمة على مدى فترة تسجيل قصيرة.

Applied DNA Sciences 报告在 Form 4 上出现内部股权变动。 一名董事在 2025/10/17 以 报价 $0(交易代码 A)购买了 18,691 股普通股。 交易后,报告人实际控制着 18,694 股直接持有

该备案指出,100% 的受限股单位在 授予日期后 90 天 赎回,表明奖励结构与短期 vesting 期内的服务相关。

Positive
  • None.
Negative
  • None.

Applied DNA Sciences ha riportato un cambiamento di capitale da insider su un modulo 4. Un amministratore ha acquisito 18.691 azioni ordinarie il 17/10/2025 con un prezzo riportato di $0 (codice di transazione A). A seguito della transazione, la persona che riporta possiede beneficamente 18.694 azioni, detenute direttamente.

La dichiarazione indica che il 100% delle Restricted Stock Units matura entro 90 giorni dalla data di attribuzione, indicando la struttura dell'assegnazione legata al servizio durante un breve periodo di vesting.

Applied DNA Sciences reportó un cambio de capital de insiders en un Form 4. Un director/a adquirió 18,691 acciones comunes el 17/10/2025 con un precio informado de $0 (código de transacción A). Tras la operación, la persona que reporta posee beneficiosamente 18,694 acciones, mantenidas directamente.

La presentación señala que el 100% de las unidades de acciones restringidas vencen tras 90 días desde la fecha de la concesión, indicando la estructura del premio ligada al servicio durante un corto periodo de vesting.

Applied DNA Sciences는 Form 4에 내부자 지분 변경을 보고했습니다. 이사는 일반 주식 18,691주2025-10-17에 매입했고 보고된 가격은 $0 (거래 코드 A)입니다. 거래 후 보고자는 직접 보유18,694주의 주식을 지분 보유합니다.

파일링에는 제한 주식 선발의 100%그 주식 부여일로부터 90일 이내에 비로소 취득된다고 적혀 있어, 짧은 vesting 기간 동안의 서비스에 연계된 보상 구조를 나타냅니다.

Applied DNA Sciences a rapporté un changement d'intérêts d'initié sur un formulaire 4. Un administrateur a acquis 18 691 actions ordinaires le 17/10/2025 avec un prix indiqué de $0 (code de transaction A). Suite à la transaction, la personne déclarant détient bénévolement 18 694 actions, détenues directement.

Le dossier indique que 100% des unités d'actions restreintes se vénent 90 jours après la date d'attribution, indiquant la structure de la récompense liée au service sur une courte période de vesting.

Applied DNA Sciences meldete eine Insider-Aktienänderung auf einem Formular 4. Ein Direktor erwarb 18.691 Stammaktien am 17.10.2025 zu einem berichteten Preis von $0 (Transaktionscode A). Nach der Transaktion besitzt die meldende Person vorteilhaft 18.694 Aktien, direkt gehalten.

Die Einreichung vermerkt, dass 100% der Restricted Stock Units fällig werden 90 Tage nach dem Ausübungsdatum, was die Preisstruktur zeigt, die an eine Dienstzeit über einen kurzen Vesting-Zeitraum gebunden ist.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Murrah Judith

(Last) (First) (Middle)
50 HEALTH SCIENCES DRIVE

(Street)
STONY BROOK NY 11790

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
APPLIED DNA SCIENCES INC [ BNBX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock(1) 10/17/2025 A 18,691 A $0 18,694 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. 100% of the restricted stock units vest upon 90 days from the date of grant
/s/ Beth Jantzen, Attorney-in-Fact 10/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did APDN report in this Form 4?

A director acquired 18,691 shares of common stock on 10/17/2025 at a reported price of $0.

How many APDN shares does the reporting person now own?

The reporting person beneficially owns 18,694 shares following the transaction, held directly.

What is the transaction code and what does it signify?

The transaction code is A, which indicates an acquisition such as a grant or award.

What vesting terms are disclosed for the award?

The filing states 100% of the restricted stock units vest upon 90 days from the date of grant.

What is the reporting person’s relationship to APDN?

The reporting person is a Director of Applied DNA Sciences.

Was the ownership reported as direct or indirect?

The ownership was reported as Direct (D).
Applied Dna Scie

NASDAQ:APDN

APDN Rankings

APDN Latest News

APDN Latest SEC Filings

APDN Stock Data

7.26M
1.28M
1.11%
6.92%
8.4%
Diagnostics & Research
Services-testing Laboratories
Link
United States
STONY BROOK